381 related articles for article (PubMed ID: 17296311)
21. Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.
Serova M; Galmarini CM; Ghoul A; Benhadji K; Green SR; Chiao J; Faivre S; Cvitkovic E; Le Tourneau C; Calvo F; Raymond E
Br J Cancer; 2007 Sep; 97(5):628-36. PubMed ID: 17637678
[TBL] [Abstract][Full Text] [Related]
22. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies.
Réjiba S; Bigand C; Parmentier C; Hajri A
Neoplasia; 2009 Jul; 11(7):637-50. PubMed ID: 19568409
[TBL] [Abstract][Full Text] [Related]
23. Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer.
Komori S; Osada S; Mori R; Matsui S; Sanada Y; Tomita H; Tokuyama Y; Takahashi T; Yamaguchi K; Yoshida K
Pancreas; 2010 Nov; 39(8):1284-92. PubMed ID: 20944490
[TBL] [Abstract][Full Text] [Related]
24. Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models.
D'Aronzo M; Vinciguerra M; Mazza T; Panebianco C; Saracino C; Pereira SP; Graziano P; Pazienza V
Oncotarget; 2015 Jul; 6(21):18545-57. PubMed ID: 26176887
[TBL] [Abstract][Full Text] [Related]
25. Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer.
Ashida R; Nakata B; Shigekawa M; Mizuno N; Sawaki A; Hirakawa K; Arakawa T; Yamao K
J Exp Clin Cancer Res; 2009 Jun; 28(1):83. PubMed ID: 19531250
[TBL] [Abstract][Full Text] [Related]
26. Human equilibrative nucleoside transporter-1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma.
Attia F; Fathy S; Anani M; Hassan A; Attia F; Ibrahim G; Elazab M
J Clin Lab Anal; 2020 Nov; 34(11):e23457. PubMed ID: 32671914
[TBL] [Abstract][Full Text] [Related]
27. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
[TBL] [Abstract][Full Text] [Related]
28. Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer.
Yoon KA; Woo SM; Hong EK; Jung MK; Park WS; Bae K; Han SS; Kim TH; Koh YH; Park SJ; Lee WJ
Oncology; 2015; 89(6):345-50. PubMed ID: 26418006
[TBL] [Abstract][Full Text] [Related]
29. Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.
Lee JT; Campbell DO; Satyamurthy N; Czernin J; Radu CG
J Nucl Med; 2012 Feb; 53(2):275-80. PubMed ID: 22302964
[TBL] [Abstract][Full Text] [Related]
30. Quantitative real time PCR of deoxycytidine kinase mRNA by Light Cycler PCR in relation to enzyme activity and gemcitabine sensitivity.
Sigmond J; Kroep JR; Loves W; Codacci-Pisanelli G; Peters GJ
Cancer Lett; 2004 Sep; 213(2):173-9. PubMed ID: 15327832
[TBL] [Abstract][Full Text] [Related]
31. cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer.
Sève P; Mackey JR; Isaac S; Trédan O; Souquet PJ; Pérol M; Cass C; Dumontet C
Lung Cancer; 2005 Sep; 49(3):363-70. PubMed ID: 15923058
[TBL] [Abstract][Full Text] [Related]
32. Optimizing pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer: a pharmacogenetic approach.
De Pas TM; Toffalorio F; Giovannetti E; Radice D; Russo F; Angeli I; Calamai G; Spitaleri G; Catania C; Noberasco C; Milani A; Pelosi G; Danesi R; De Braud F
J Thorac Oncol; 2011 Apr; 6(4):768-73. PubMed ID: 21336182
[TBL] [Abstract][Full Text] [Related]
33. Sensitivity to gemcitabine and its metabolizing enzymes in neuroblastoma.
Ogawa M; Hori H; Ohta T; Onozato K; Miyahara M; Komada Y
Clin Cancer Res; 2005 May; 11(9):3485-93. PubMed ID: 15867251
[TBL] [Abstract][Full Text] [Related]
34. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
[TBL] [Abstract][Full Text] [Related]
35. Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer.
Pérez-Torras S; García-Manteiga J; Mercadé E; Casado FJ; Carbó N; Pastor-Anglada M; Mazo A
Biochem Pharmacol; 2008 Aug; 76(3):322-9. PubMed ID: 18589402
[TBL] [Abstract][Full Text] [Related]
36. Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.
Mitra AK; Kirstein MN; Khatri A; Skubitz KM; Dudek AZ; Greeno EW; Kratzke RA; Lamba JK
Pharmacogenomics; 2012 Jul; 13(9):1009-21. PubMed ID: 22838949
[TBL] [Abstract][Full Text] [Related]
37. Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine.
Kawasaki H; Carrera CJ; Piro LD; Saven A; Kipps TJ; Carson DA
Blood; 1993 Feb; 81(3):597-601. PubMed ID: 8094016
[TBL] [Abstract][Full Text] [Related]
38. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells.
Giovannetti E; Mey V; Nannizzi S; Pasqualetti G; Marini L; Del Tacca M; Danesi R
Mol Pharmacol; 2005 Jul; 68(1):110-8. PubMed ID: 15795320
[TBL] [Abstract][Full Text] [Related]
39. Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.
Tang K; Zhang Z; Bai Z; Ma X; Guo W; Wang Y
Oncol Rep; 2011 Apr; 25(4):963-70. PubMed ID: 21225236
[TBL] [Abstract][Full Text] [Related]
40. DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells.
Candelaria M; de la Cruz-Hernandez E; Taja-Chayeb L; Perez-Cardenas E; Trejo-Becerril C; Gonzalez-Fierro A; Chavez-Blanco A; Soto-Reyes E; Dominguez G; Trujillo JE; Diaz-Chavez J; Duenas-Gonzalez A
PLoS One; 2012; 7(3):e29181. PubMed ID: 22427797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]